MAPT and Alzheimer disease: For example, CSF p‐tau and tau PET are both incorporated as markers of tau pathology in the most recent research criteria for AD (Jack et al, 2018a), and both can be used to define “T” (tau) status in the AT(N) classification system (Jack et al, 2016).